200 related articles for article (PubMed ID: 28927305)
1. Discovery and application of immune biomarkers for hematological malignancies.
Zafeiris D; Vadakekolathu J; Wagner S; Pockley AG; Ball GR; Rutella S
Expert Rev Mol Diagn; 2017 Nov; 17(11):983-1000. PubMed ID: 28927305
[TBL] [Abstract][Full Text] [Related]
2. Programming the immune checkpoint to treat hematologic malignancies.
Vick E; Mahadevan D
Expert Opin Investig Drugs; 2016 Jul; 25(7):755-70. PubMed ID: 27070269
[TBL] [Abstract][Full Text] [Related]
3. A new perspective on hematological malignancies: m6A modification in immune microenvironment.
Yang S; Xu L; Zhuang H; Li F; Lu Y
Front Immunol; 2024; 15():1374390. PubMed ID: 38868768
[TBL] [Abstract][Full Text] [Related]
4. The DNA methylation landscape of hematological malignancies: an update.
Blecua P; Martinez-Verbo L; Esteller M
Mol Oncol; 2020 Aug; 14(8):1616-1639. PubMed ID: 32526054
[TBL] [Abstract][Full Text] [Related]
5. [Proteomics techniques and their application in haemato-oncologic malignancies].
Zelená J; Hájek R
Cas Lek Cesk; 2007; 146(7):586-92. PubMed ID: 17722845
[TBL] [Abstract][Full Text] [Related]
6. Dissecting the Immune Landscape of Acute Myeloid Leukemia.
Davidson-Moncada J; Viboch E; Church SE; Warren SE; Rutella S
Biomedicines; 2018 Nov; 6(4):. PubMed ID: 30477280
[TBL] [Abstract][Full Text] [Related]
7. Reprogramming Tumor-Immune Cell Interface in Solid and Hematological Malignancies to Enhance Response to Therapy.
Di Martino MT; Zazzeroni F; Donadelli M; Chiodoni C; Caraglia M; Scotlandi K; Meschini S; Leonetti C
J Exp Clin Cancer Res; 2018 Mar; 37(1):48. PubMed ID: 29506548
[No Abstract] [Full Text] [Related]
8. Immune checkpoint blockade in lymphoid malignancies.
Thanarajasingam G; Thanarajasingam U; Ansell SM
FEBS J; 2016 Jun; 283(12):2233-44. PubMed ID: 26807978
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of hematological malignancies using dendritic cells.
Van de Velde AL; Berneman ZN; Van Tendeloo VF
Bull Cancer; 2008 Mar; 95(3):320-6. PubMed ID: 18390412
[TBL] [Abstract][Full Text] [Related]
10. Immune Modulation in Hematologic Malignancies.
Dhodapkar MV; Dhodapkar KM
Semin Oncol; 2015 Aug; 42(4):617-25. PubMed ID: 26320065
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity.
Ramsay AG
Br J Haematol; 2013 Aug; 162(3):313-25. PubMed ID: 23691926
[TBL] [Abstract][Full Text] [Related]
12. Integrative oncogenomic analysis of microarray data in hematologic malignancies.
Martínez-Climent JA; Fontan L; Fresquet V; Robles E; Ortiz M; Rubio A
Methods Mol Biol; 2010; 576():231-77. PubMed ID: 19882266
[TBL] [Abstract][Full Text] [Related]
13. [NGS-based multi-gene panel testing in hematological malignancies: diagnosis and prognostic prediction].
Tanigawa T; Kataoka K
Rinsho Ketsueki; 2022; 63(4):294-301. PubMed ID: 35491219
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of current cancer immunotherapy: hemato-oncology.
Hourigan CS; Levitsky HI
Cancer J; 2011; 17(5):309-24. PubMed ID: 21952281
[TBL] [Abstract][Full Text] [Related]
15. Role of tumor-associated macrophages in hematological malignancies.
Komohara Y; Niino D; Ohnishi K; Ohshima K; Takeya M
Pathol Int; 2015 Apr; 65(4):170-6. PubMed ID: 25707506
[TBL] [Abstract][Full Text] [Related]
16. [Progress in Immunotherapy for Hematological Malignancies].
Yasukawa M
Nihon Naika Gakkai Zasshi; 2016 Jun; 105(6):1061-8. PubMed ID: 30168700
[No Abstract] [Full Text] [Related]
17. How immunology is reshaping clinical disciplines: the example of haematology.
Caligaris-Cappio F
Lancet; 2001 Jul; 358(9275):49-55. PubMed ID: 11454399
[TBL] [Abstract][Full Text] [Related]
18. Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies.
Tsirigotis P; Savani BN; Nagler A
Ann Med; 2016 Sep; 48(6):428-439. PubMed ID: 27224873
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive characterization of TGFB1 across hematological malignancies.
Wang CZ; Zhang ZQ; Zhang Y; Zheng LF; Liu Y; Yan AT; Zhang YC; Chang QH; Sha S; Xu ZJ
Sci Rep; 2023 Nov; 13(1):19107. PubMed ID: 37925591
[TBL] [Abstract][Full Text] [Related]
20. Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies.
Ye B; Stary CM; Gao Q; Wang Q; Zeng Z; Jian Z; Gu L; Xiong X
J Immunol Res; 2017; 2017():5210459. PubMed ID: 28116322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
